Showing results (181-190 of 192) with videos related to
Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical OutcomesJustin Hwang, Xiaolei Shi, Andrew Elliott, et al.European Urology|May 13, 2026
IDH1 Mutations Are Associated with Favorable Outcomes in Prostate CancerLuka Cavka, Subhiksha Nandakumar, Qingqing Wu, et al.Oncogene|November 3, 2021
Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancerHiroyuki Arai, Andrew Elliott, Joshua Millstein, et al.Cell Reports. Medicine|June 26, 2026
Case of complete response to immunotherapy in MMR-deficient prostate cancer associated with NK-like and CD4+CD8+ T cellsAlexander K Tsai, John R Lozada, Philippa R Kennedy, et al.Frontiers in Oncology|March 25, 2021
Beginning Restorative Activities Very Early: Implementation of an Early Mobility Initiative in a Pediatric Onco-Critical Care UnitSaad Ghafoor, Kimberly Fan, Sarah Williams, et al.The Oncologist|June 19, 2025
REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimensJeffrey Zhong, Albert Jang, Bashar Abuqayas, et al.Journal for Immunotherapy of Cancer|July 22, 2026
Intratumoral TIGIT blockade augments antitumor responses and bypasses increased functionality of peripheral TIGIT+ NK cells in mouse and human models of bone and soft tissue sarcomaMarshall L Lammers, Cyrus J Sholevar, Makan Karimzadeh, et al.Cancer Discovery|February 26, 2026
A tumor-promoting inflammatory SPP1+ macrophage-IL-6-CRP axis drives immune dysfunction in bladder cancerMichelle A Tran, Byuri Angela Cho, Sudeh Izadmehr, et al.European Urology Oncology|December 10, 2023
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate CancerJacob J Orme, Fadi Taza, Navonil De Sarkar, et al.Cancer Discovery|April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET InhibitorsFederica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.Pageof 20